US1280583022 - Common Stock
LISATA THERAPEUTICS INC
NASDAQ:LSTA (5/7/2024, 7:08:10 PM)
Premarket: 2.8 +0.05 (+1.82%)2.75
-0.02 (-0.72%)
Lisata Therapeutics, Inc. develops biopharmaceuticals. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. The firm is engaged in the discovery, development, and commercialization of therapies for the treatment of advanced solid tumors and other diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). LSTA1 also has the potential to modify the tumor microenvironment. The company is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. In addition, it has clinical development programs based on its autologous CD34+ cell therapy technology platform.
LISATA THERAPEUTICS INC
110 Allen Road, Second Floor
Basking Ridge NEW JERSEY
P: 19082292590
Employees: 27
Website: https://www.lisata.com/
BASKING RIDGE, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Results of Phase 1b/2 in China reinforce global clinical development rationale and plans for LSTA1
Results of Phase 1b/2 in China reinforce global clinical development rationale and plans for LSTA1...
Here you can normally see the latest stock twits on LSTA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: